TIEFENBACHER API + INGREDIENTS offer GMP certificated Natural Medicinal Cannabidiol (CBD) with highest purity profile in the market

We bring pharma-quality standards of cannabis API for the benefit of Patients in Europe. CBD, short for Cannabidiol, is a chemical compound from the Cannabis sativa plant. It has no psychotropic effects due to it is affinity for cannabinoid receptors CB1 and CB2 and which are part of the endocannabinoid system (ECS).

Pharmacological effect comprehends according to the medical literature positives effects in different autoimmune and neurogenerative pathologies such as multiple sclerosis (spasticity), arthritis, epilepsy (Lennox-Gastaut Syndrome and Dravet Syndrome), schizophrenia and other psychiatric disorders.

TIEFENBACHER API + INGREDIENTS can offer a CBD – white, crystalline substance isolated from industrial hemp in its purest form – manufactured in Europe with a purity > 99,5%, and an impurity profile of THC < 0,01%. By that minimizing side effects for patients.

Our partner for natural CBD is having a MHRA certified EU GMP certificate for both, human and veterinary use and complies with the requirements of the German Medicines Codex (DAC).

TIEFENBACHER API + INGREDIENTS covers the entire supply chain for medical cannabis with the highest pharmaceutical standards. For more information, please contact TIEFENBACHER API + INGREDIENTS: Patricia Wick p.wick@tifi-api.eu


TIEFENBACHER API + INGREDIENTS secures the supply of critical drug for COVID-19 Patients: Dexmedetomidine Hydrochloride

We ensure hospitals have access to the medicines needed for patient care, including Dexmedetomidine HCL. TIEFENBACHER API + INGREDIENTS delivers long-term solutions that help deliver top quality patient care throughout the pandemic and beyond.

Dexmedetomidine HCl, a novel sedative-analgesic agent and a front-line drug in our intensive care units becomes increasingly important for patients while it is on the FDA’s Drug Shortage List. The sudden rise is attributable to the global COVID-19 pandemic as Dexmedetomidine HCl  injectable is used to help put COVID-19 patients on to medical ventilators.

Its rising tendency is however expected to sustain beyond COVID-19 as tremendous research is being performed based on its advantageous sedating and analgesic properties compared to other alpha 2 agonists.

Dexmedetomidine HCl is currently being investigated and researched in various fields like e.g. Transdermal formulations, Intranasal formulations for treating pain, Oral thin film formulations and Dexmedetomidine slow release microneedle array.

In  veterinary practice  Dexmedetomidine HCl  is used for premedication and as an adjunct to general anesthesia.

Dexmedetomidine Hydrochloride is immediately  available – and our whole portfolio includes more than 600+ APIs to secure the healthcare industry. For more information, please contact TIEFENBACHER  API + INGREDIENTS:  Sandra Thiel s.thiel@tifi-api.eu


New TIEFENBACHER API website – part of the TIEFENBACHER GROUP Brand Relaunch

“We are very thrilled to officially announce our new TIEFENBACHER API website, representing the raw material business of TIEFENBACHER GROUP, and aiming to expand our role as a high-quality distributor for active pharmaceutical ingredients. Our new website communicates a clear message of who we are, what we rise for and where our value lies when delivering on our best value seal: BETTER ACCESS, BETTER QUALITY, and BETTER SUPPLY.

The new API Website is an important milestone within the international brand relaunch of our whole company group (www.tiefenbachergroup.com) and represents the fundamental changes which we have started in the recent years. We are on the move to drive important efficiencies in our supply chain and become a more and more innovative, patient-centered enterprise with a global pharmaceutical footprint.”

Sören Schlosser and Oliver Schrader, Managing Directors TIEFENBACHER API

“We are very thrilled to officially announce our new TIEFENBACHER API website, representing the raw material business of TIEFENBACHER GROUP, and aiming to expand our role as a high-quality distributor for active pharmaceutical ingredients. Our new website communicates a clear message of who we are, what we rise for and where our value lies when delivering on our best value seal: BETTER ACCESS, BETTER QUALITY, and BETTER SUPPLY.

The new API Website is an important milestone within the international brand relaunch of our whole company group (www.tiefenbachergroup.com) and represents the fundamental changes which we have started in the recent years. We are on the move to drive important efficiencies in our supply chain and become a more and more innovative, patient-centered enterprise with a global pharmaceutical footprint.”

Sören Schlosser and Oliver Schrader, Managing Directors TIEFENBACHER API


Tiefenbacher Group and OnDosis enter a strategic partnership for game-changing integration of medicines and digital health

Tiefenbacher Group and OnDosis today announced the signing of an extensive co-development agreement for multiple products in the upcoming years. This collaboration strengthens both companies’ commitment to further develop and commercialize innovative products within individualized treatments and digital health, combining traditional drug-based medicines with digital therapeutics and intelligent dosing.